We improve the lives of people with chronic conditions by improving pharmaceutical policies to optimise medical treatments, facilitate equal access to medications, and foster transparency.
This node forms part of the Evidence, Policy and Influence Collaborative (EPIC).
Are pharmaceutical policies in Australia based on evidence or influence? We answer this question collaborating with consumers and medical professionals to research on policy, evidence and influence related to drug therapies for obesity, diabetes, cardiovascular disease, cancer, ageing and mental health.
Our goal is to inform policy debates with high quality evidence in order to develop solutions for optimizing treatment for patients affected by chronic disease. We give evidence-based responses to controversial aspects of drug-therapies such as: influence on health consumers and medical professionals by the pharmaceuticals industry, equal access to medications, and over-prescribing.
The project node works to improve treatment, with or without drugs, for patients affected by chronic disease, as well as increase transparency in pharmaceutical policies. Examples include: analysis of the role of drug therapies for obesity, evaluation of the increased access to insulin analogues in low-income countries, examination of the warnings by regulators about newly discovered harmful effects of medicines.
Consolidation of a research team including University of Sydney, University of New South Wales, University of South Australia, Harvard, University of Copenhagen, Utrecht University, Kings College London, University of British Columbia, York University, Dalhousie University has resulted in 8 publications thus far, along with 3 under submission and an additional 6-8 expected. Highlights include:
We have developed research databases on pharmaceutical industry payments to health professionals and consumer organisations in Australia. These have been used as a resource by journalists and led to media coverage on undue influence on health care via sponsorship of educational events for health professionals, consumer health organisations, individual professional financing for speaking engagements, advisory boards, travel, conference attendance, and contracts.
Pharmaceutical regulatory policy issues
Submissions to consultations on pharmaceutical regulatory policy issues include:
Advisory committee members